Differential expression of wild-type and mutant NMMHC-IIA polypeptides in blood cells suggests cell-specific regulation mechanisms in MYH9 disorders

Blood

Volumn 111, Issue 6, 2008, Pages 3015-3023

  Kunishima, Shinji ^a   Hamaguchi, Motohiro ^a   Saito, Hidehiko ^b  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b NAGOYA CENTRAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CD34 ANTIBODY; MYOSIN IIA; NT 629; POLYCLONAL ANTIBODY; POLYPEPTIDE; UNCLASSIFIED DRUG; ANTIBODY; MESSENGER RNA; MOLECULAR MOTOR; MYH9 PROTEIN, HUMAN; MYOSIN HEAVY CHAIN; PEPTIDE;

ADOLESCENT; ADULT; ARTICLE; BLOOD CELL; CARBOXY TERMINAL SEQUENCE; CASE REPORT; CELL INCLUSION; CHILD; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; LAMELLIPODIUM; LYMPHOCYTE; MALE; MEGAKARYOCYTE; MONOCYTE; MYH9 GENE; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; SCHOOL CHILD; THROMBOCYTE; THROMBOCYTOPENIA; AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; GENE EXPRESSION REGULATION; GENETICS; HEMATOLOGIC DISEASE; IMMUNOLOGY; INFANT; METABOLISM; MOLECULAR GENETICS; MUTATION; PRESCHOOL CHILD;

ADULT; AMINO ACID SEQUENCE; ANTIBODIES; ANTIBODY SPECIFICITY; BASE SEQUENCE; BLOOD CELLS; CHILD; CHILD, PRESCHOOL; CYTOPLASM; FEMALE; GENE EXPRESSION REGULATION; HEMATOLOGIC DISEASES; HUMANS; INCLUSION BODIES; INFANT; MALE; MEGAKARYOCYTES; MOLECULAR MOTOR PROTEINS; MOLECULAR SEQUENCE DATA; MUTATION; MYOSIN HEAVY CHAINS; PEPTIDES; RNA, MESSENGER;

EID: 42449140234     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-10-116194     Document Type: Article

References (40)

1. Hegglin R. Gleichzeitige konstitutionelle Veranderungen an Neutrophilen und Thrombocyten. Helv Med Acta. 1945;12:439-440.
2. May R. Leukozyteneinschlusse. Dtsch Arch Klin Med. 1909;96:1-6.
3. Saito H. Kunishima S. Historical hematology: May-Hegglin anomaly. Am J Hematol. 2007 Nov 1; [Epub ahead of print].
4. Kelley MJ, Jawien W, Ortel TL, Korczak JF. Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly. Nat Genet. 2000;26:106-108.
5. Kunishima S, Kojima T, Matsushita T, et al. Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome). Blood. 2001;97:1147-1149.
6. The May-Hegglin/Fechtner Syndrome Consortium. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. Nat Genet. 2000;26:103-105.
7. Dong F, Li S, Pujol-Moix N. et al. Genotype-phenotype correlation in MYH9-related thrombocytopenia. Br J Haematol. 2005;130:620-627.
8. Heath KE, Campos-Barros A, Toren A, et al. Nonmuscle myosin heavy chain llA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian. Epstein, and Alport-like syndromes. Am J Hum Genet. 2001;69:1033-1045.
9. Kunishima S, Matsushita T, Kojima T, et al. Identification of six novel MYH9 mutations and genotype-phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions. J Hum Genet. 2001;46:722-729.
10. Seri M, Pecci A, Di Bari F et al. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome. Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore). 2003;82:203-215.
11. Kunishima S, Matsushita T. Kojima T, et al. Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders: association of subcellular localization with MYH9 mutations. Lab Invest. 2003;83:115-122.
12. Deutsch S, Rideau A, Bochaton-Piallat ML, et al. Asp1424Asn MYH9 mutation results in an unstable protein responsible for the phenotypes in May-Hegglin anomaly/Fechtner syndrome. Blood. 2003;102:529-534.
13. Pecci A, Ganobbio I, Balduini A, et al. Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations. Hum Mol Genet. 2005;14:3169-3178.
14. Jenis MEH, Takeuchi A, Dillon DE, Ruymann MFB, Rivkin S. The May-Hegglin anomaly: ultrastructure of the granulocytic inclusion. Am J Clin Pathol. 1971;55:187-196.
15. Oski FA, Naiman JL Allen DM, Diamond LK. Leukocytic inclusions-Dohle bodies-associated with platelet abnormality (the May-Hegglin anomaly): report of a family and review of the literature. Blood. 1962;20:657-667.
16. Volpe E, Cuccurullo L, Valente A, Jori GP, Buonanno G. The May-Hegglin anomaly: further studies on leukocyte inclusions and platelet ultrastructure. Acta Haematol. 1974;52:238-247.
17. Kunishima S, Matsushita T, YoshiharaT et al. First description of somatic mosaicism in MYH9 disorders. Br J Haematol. 2005;128:360-365.
18. Daniel JL. Sellers JR. Purification and characterization of platelet myosin. Methods Enzymol. 1992;215:78-88.
19. Imai Y, Matsushima Y Sugimura T, Terada M. A simple and rapid method for generating a deletion by PCR. NucleicAcids Res. 1991;19:2785.
20. Maupin P, Phillips CL Adelstein RS, Pollard TD. Differential localization of myosin-ll isozymes in human cultured cells and blood cells. J Cell Sci. 1994;107:3077-3090.
21. Pecci A, Noris P, Invernizzi R, et al. Immunocytochemistry for the heavy chain of the non-muscle myosin IIA as a diagnostic tool for MYH9-related disorders. Br J Haematol. 2002;117:164-167.
22. Sellers JR. Myosins: a diverse superfamily. Biochim Biophys Acta. 2000:1496:3-22.
23. Franke JD, Dong F Rickoll WL Kelley MJ, Kiehart DP. Rod mutations associated with MYH9-related disorders disrupt nonmuscle myosin-IIA assembly. Blood. 2005;105:161-169.
24. Gerecedo D, Stock R, Gonzalez S, Reyes E, Mondragon R. Modification of actin, myosin and tubulin distribution during cytoplasmic granule movements associated with platelet adhesion. Haematologica. 2002;87:1165-1176.
25. Tanaka K, Shibata N, Okamoto K, et al. Reorganization of myosin in surface-activated spreading platelets. J Ultrastruct Mol Struct Res. 1986:97: 165-186.
26. White JG. Arrangements of actin filaments in the cytoskeleton of human platelets. Am J Pathol. 1984;117:207-217.
27. Jennings LK, Fox JE, Edwards HH, Phillips DR. Changes in the cytoskeletal structure of human platelets following thrombin activation. J Biol Chem. 1981;256:6927-6932.
28. Tanaka K, Itoh K. Reorganization of stress fiberlike structures in spreading platelets during surface activation. J Struct Biol. 1998:124:13-41.
29. Canobbio I, Noris P, Pecci A, Balduini A, Balduini CL, Torti M. Altered cytoskeleton organization in platelets from patients with MYH9-related disease. J Thromb Haemost. 2005;3:1026-1035.
30. Leon C, Eckly A, Hechler B, et al. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. Blood. 2007;110:3183-3191.
31. Godwin HA. Ginsburg AD. May-Hegglin anomaly: a defect in megakaryocyte fragmentation? Br J Haematol. 1974;26:117-128.
32. Hamilton RW, Shaikh BS. Ottie JN. StorchAE, Saleem A, White JG. Platelet function, ultrastructure, and survival in the May-Hegglin anomaly. Am J Clin Pathol. 1980;74:663-668.
33. Chang Y Aurade F, Larbret F, et al. Proplatelet formation is regulated by the Rho/ROGK pathway. Blood. 2007;109:4229-4236.
34. Chen Z, Naveiras O, Balduini A, et al. The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. Blood. 2007;110:171-179.
35. Schulze H, Shivdasani RA. Mechanisms of thrombopoiesis. J Thromb Haemost. 2005:3: 1717-1724.
36. Matsushita T, Hayashi H, Kunishima S, etal. Targeted disruption of mouse ortholog of the human MYH9 responsible for macrothrombocytopenia with different organ involvement: hematological, nephrological, and otological studies of heterozygous KO mice. Biochem Biophys Res Commun. 2004:325:1163-1171.
37. MhatreAN, LiY, Bhatia N; Wang KH, Atkin G, Lalwani AK. Generation and characterization of mice with Myh9 deficiency. Neuromolecular Med. 2007:9:205-215.
38. Kunishima S, Yoshinari M, Nishio H, et al. Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations. Eur J Haematol. 2007:78:220-226.
39. Fink L, Holschermann H, Kwapiszewska G, et al. Characterization of platelet-specific mRNA by real-time PCR after laser-assisted microdissection. Thromb Haemost. 2003;90:749-756.
40. Chung MC. Kawamoto S. IRF-2 is involved in upregulation of nonmuscle myosin heavy chain ll-A gene expression during phorbol ester-induced promyelocytic HL-60 differentiation. J Biol Chem. 2004;279:56042-56052.